可注射的富有血小板的纤维素是否真的有效降低移除受影响的第三牙手术的预期副作用?
Hasan Akpınar1, Ferhat Ayrancı2
1Research Assistant, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ordu University, Ordu, Turkiye.
概括
可注射的富血小板纤维素 (i-PRF) 在第三手术后对疼痛的影响有限,但有效降低了手术后的胀. 建议进行进一步的研究,以详细发现i-PRF的疗效.
科学领域:
- 口腔和牙面部外科手术
- 再生医学是一种再生医学.
- 临床牙科 临床牙科
背景情况:
- 第三 (M3) 手术通常会导致疼痛,和三,对患者的生活质量产生负面影响.
- 正在研究可注射的富血小板纤维素 (i-PRF) 作为减轻这些不良影响的潜在方法.
研究的目的:
- 为了比较i-PRF与对照药物的疗效,在治疗疼痛,胀,三症和M3切除后的生活质量方面.
- 量化i-PRF治疗侧和对照侧关键术后结果的差异.
主要方法:
- 进行了一项单中心,分口,随机的前性临床试验.
- 包括35名接受M3提取的患者,其中i-PRF应用在一侧,对照在另一侧.
- 包括疼痛,止痛药消耗,胀,口腔打开和生活质量在内的结果使用经过验证的秤和测量来评估.
主要成果:
- i-PRF在减少术后瘤方面表现出显著的有效性,在手术后的特定日子里,侧面的canthus-angulus和tragus-commisura距离有可测量的差异.
- 虽然i-PRF没有显著影响术后疼痛水平,但它导致了止痛药消耗的显著减少.
- 没有观察到i-PRF对术后生活质量的显著影响,在第二天,i-PRF侧的口腔开口减少了.
结论:
- 在第三手术后,i-PRF显示了在治疗术后胀的潜力.
- 它对疼痛管理的影响是有限的,需要进一步研究.
- 需要进行更大规模的研究,以更全面地了解i-PRF的临床效用.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
537
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
537
Clot Retraction and Fibrinolysis
6.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.3K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Formation of the Platelet Plug
6.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


